A mathematical model for the administration of temozolomide: comparative analysis of conventional and metronomic chemotherapy regimens

Pilot study of a pediatric metronomic 4-drug regimen

(2015) Nicolas André et al.   Oncotarget

Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment

(2015) Eddy Pasquier et al.   Oncotarget

Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience

(2012) D. Zapletalova et al.   ONCOLOGY

Chemoresistance to Temozolomide in Human Glioma Cell Line U251 is Associated with Increased Activity of O 6-methylguanine-DNA Methyltransferase and Can be Overcome by Metronomic Temozolomide Regimen

(2011) Qiang Pan et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?

(2011) Raffaele Addeo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Nontoxic, Fiscally Responsible, Future of Oncology

(2010) Giannoula Lakka Klement et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Metronomic chemotherapy: new rationale for new directions

(2010) Eddy Pasquier et al.   Nature Reviews Clinical Oncology

An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics

(2008) C. Meille et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS